Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Avalyn Pharma Inc. (AVLN)

Avalyn Pharma appoints Robert Meyer, M.D. as Class II director effective September 15, 2026

Neutral Impact 2 of 5 leadership Written later

Avalyn Pharma's board appointed Robert Meyer, M.D. as a Class II director effective September 15, 2026, with a term expiring at the 2028 annual meeting. The board determined he is independent under Nasdaq listing standards, and he brings prior FDA and drug-regulatory experience.

Key points

  • Robert Meyer, M.D. appointed Class II director effective September 15, 2026; term expires at the 2028 annual meeting
  • Annual director retainer of $40,000 under the Non-Employee Director Compensation Policy
  • Initial option grant for 31,182 shares of common stock, vesting in equal annual installments over three years

The filing

CompanyAvalyn Pharma Inc. (AVLN)
Form8-K, current report
Filed with the SECSep 16, 2026, 4:13 PM ET
Accession number0001193125-26-393081

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.